Table 7.

Mean costs, QALYs and incremental cost-effectiveness ratios for the CARDERA trial.

	Monotherapy	Combination therapies
	MTX	MTX+CS	MTX+PNS	MTX+CS+PNS
Total costsa	£7503	£6829	£6323	£6203
EQ-5D-3L from trial data
Total QALYs	1.238	1.093	1.152	1.320
ICER (for col therapy vs. row therapy)
MTX only	–	£4648	£13,714	–£15,929
MTX+CS	£4648	–	–£8597	-£2765
MTX+PNS	£13,714	–£8597	–	–£714
EQ-5D-5L mapped from 3L trial data (full joint copula-mixture model)
Total QALYs	1.450	1.351	1.382	1.513
ICER (for col therapy vs. row therapy)
MTX only	–	£6,755	£17,264	–£20,728
MTX+CS	£6755	–	–£ 16,140	–£3,857
MTX+PNS	£17,264	–£ 16,140	–	–£917
EQ-5D-5L mapped from 3L trial data for restricted models
Demographic covariates only
Total QALYs	1.437	1.326	1.359	1.480
ICER (for col therapy vs. row therapy)
MTX only	–	£6054	£15,137	–£30,466
MTX+CS	£6054	–	–£15,198	–£4070
MTX+PNS	£15,137	–£15,198	–	–£996
Independent domains
Total QALYs	1.462	1.376	1.404	1.531
ICER (for col therapy vs. row therapy)
MTX only	–	£7851	£20,361	–£18,696
MTX+CS	£7851	–	–£18,179	–£4033
MTX+PNS	£20,361	–£18,179	–	–£942
Joint Gaussian model
Total QALYs	1.453	1.353	1.384	1.514
ICER (for col therapy vs. row therapy)
MTX only	–	£6818	£17,409	–£20,708
MTX+CS	£6,818	–	–£16,324	–£3877
MTX+PNS	£17,409	–£16,324	–	–£920

^aPresent value of treatment costs over the 2-year experimental period.